Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy

被引:181
作者
Blair, SN
Capuzzi, DM
Gottlieb, SO
Nguyen, T
Morgan, JM
Cater, NB
机构
[1] Cooper Inst, Dallas, TX 75230 USA
[2] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA
[3] Midatlantic Cardiovasc Associates, Baltimore, MD USA
[4] Mayo Clin, Rochester, MN USA
[5] Univ Texas, SW Med Ctr, Dallas, TX USA
关键词
D O I
10.1016/S0002-9149(00)00976-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study compares the effect of plant stanol ester spread with a placebo spread on cholesterol in patients taking statin therapy, but who still had elevated low-density lipoprotein (LDL) cholesterol. This was a randomized, double-blind, placebo-controlled clinical trial, with 67 women and 100 men with LDL cholesterol greater than or equal to 130 mg/dl and triglycerides less than or equal to 350 mg/dl who had been taking a stable dose of a statin drug for at least 90 days before the start of the study. For 8 weeks, participants consumed 3 servings/day of the plant stanol ester spread that provided 5.1 g/day of plant stanol ester or a placebo. The addition of plant stanol ester spread significantly reduced total cholesterol and LDL cholesterol at 2, 4, and 8 weeks when compared with placebo spread. Plant stanol ester spread reduced total cholesterol at 8 weeks by 12% compared with a placebo reduction of 5% (-7% difference; p <0.0001). Plant stanol ester spread reduced LDL cholesterol at 8 weeks by 17% compared with a 7% reduction in the placebo group (-10% difference, p <0.0001). The absolute reduction in LDL cholesterol at 8 weeks was 24 and 10 mg/dl in the stanol ester and placebo groups, respectively. The plant stanol ester spread group also had greater reductions in both serum total cholesterol and LDL cholesterol than the placebo group at 2 and 4 weeks (p <0.001 for all comparisons). Both spreads were well tolerated by study participants, and no significant adverse events were noted. Consumption of spread that provided 5.1 g/day of plant stanol esters effectively reduced elevated total and LDL cholesterol levels in participants on a stable regimen of a statin. (C) 2000 by Excerpta Medico, Inc.
引用
收藏
页码:46 / 52
页数:7
相关论文
共 21 条
  • [1] TREATMENT OF SEVERE FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDHOOD WITH SITOSTEROL AND SITOSTANOL
    BECKER, M
    STAAB, D
    VONBERGMANN, K
    [J]. JOURNAL OF PEDIATRICS, 1993, 122 (02) : 292 - 296
  • [2] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA
    BRADFORD, RH
    SHEAR, CL
    CHREMOS, AN
    DUJOVNE, C
    DOWNTON, M
    FRANKLIN, FA
    GOULD, AL
    HESNEY, M
    HIGGINS, J
    HURLEY, DP
    LANGENDORFER, A
    NASH, DT
    POOL, JL
    SCHNAPER, H
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) : 43 - 49
  • [3] Cater NB, 1999, EUR HEART J SUPPL, V1, pS36
  • [4] Cater NB, 1998, NEW DEV DIETARY MANA, P6
  • [5] New lipid lowering drugs and new effects of old drugs
    Dujovne, CA
    [J]. CURRENT OPINION IN LIPIDOLOGY, 1997, 8 (06) : 362 - 368
  • [6] FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
  • [7] Grundy SR, 1999, EUR HEART J SUPPL, V1, pS132
  • [8] Gylling H, 1997, CIRCULATION, V96, P4226
  • [9] SERUM-CHOLESTEROL AND CHOLESTEROL AND LIPOPROTEIN METABOLISM IN HYPERCHOLESTEROLEMIC NIDDM PATIENTS BEFORE AND DURING SITOSTANOL ESTER-MARGARINE TREATMENT
    GYLLING, H
    MIETTINEN, TA
    [J]. DIABETOLOGIA, 1994, 37 (08) : 773 - 780
  • [10] GYLLING H, 1995, J LIPID RES, V36, P1807